Objective: To probe into the clinical efficacy of voriconazole in the treatment of invasive fungal infection in children in pediatric intensive care unit (PICU). Methods: Twenty-five children from PICU who were treated with voriconazole for fungal infection during hospitalization from Sept. 2019 to May 2020 were extracted to analyze the purpose of medication

host factors

imaging manifestations

microbial examination and therapeutic effects. Results: The total effective rate of voriconazole in the treatment of invasive fungal infection in PICU was 52.0%. Clinical diagnosis had longer treatment course than proposed diagnosis and the difference was statistically significant. There were no statistically significant difference in the efficacy of voriconazole for children with co-infection

gender

diagnostic level (proposed and clinical diagnosis) and age (<2 and ≥2 years old). The effective rate of voriconazole was 85.7% for Aspergillus and 28.6% for Candida

the difference was statistically significant. Conclusion: The reason for the low effective rate of voriconazole in the treatment of invasive fungal infection may be related to the complicated underlying diseases of children from PICU

leading to the ineffective control of antifungal therapy. Voriconazole has significant effect on invasive Aspergillosis

but poor effect on Candida. The presence or absence of co-infection

gender

diagnostic level and age do not affect the efficacy of voriconazole.